The present invention discloses a benzyl phenyl ether derivative, a preparation method therefor, and a pharmaceutical composition and uses thereof. Specifically, the invention relates to benzyl phenyl ether derivatives represented by formula (I), a pharmaceutically-acceptable salt thereof, a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition containing the one or more compounds, and uses of the compounds in treating diseases related to PD-1/PD-L1 signal channels, such as cancers, infectious diseases and autoimmune diseases.

##STR00001##

The present invention discloses a benzyl phenyl ether derivative, a preparation method therefor, and a pharmaceutical composition and uses thereof. Specifically, the invention relates to benzyl phenyl ether derivatives represented by formula (I), a pharmaceutically-acceptable salt thereof, a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition containing the one or more compounds, and uses of the compounds in treating diseases related to PD-1/PD-L1 signal channels, such as cancers, infectious diseases and autoimmune diseases.

##STR00001##

Addition-fragmentation agents of the formula are disclosed: ##STR00001##
wherein
R.sup.1, R.sup.2 and R.sup.3 are each independently Z-Q-, a (hetero)alkyl group or a (hetero)aryl group with the proviso that at least one of R.sup.1, R.sup.2 and R.sup.3 is Z.sub.m-Q-,
Q is a linking group have a valence of m+1;
Z is an ethylenically unsaturated polymerizable group,
m is 1 to 6;
each X.sup.1 is independently O or NR.sup.4, where R.sup.4 is H or C.sub.1-C.sub.4 alkyl, and
n is 0 or 1.

Addition-fragmentation agents of the formula are disclosed: ##STR00001##
wherein
R.sup.1, R.sup.2 and R.sup.3 are each independently Z-Q-, a (hetero)alkyl group or a (hetero)aryl group with the proviso that at least one of R.sup.1, R.sup.2 and R.sup.3 is Z.sub.m-Q-,
Q is a linking group have a valence of m+1;
Z is an ethylenically unsaturated polymerizable group,
m is 1 to 6;
each X.sup.1 is independently O or NR.sup.4, where R.sup.4 is H or C.sub.1-C.sub.4 alkyl, and
n is 0 or 1.

Addition-fragmentation agents of the formula are disclosed: ##STR00001##
wherein
R.sup.1, R.sup.2 and R.sup.3 are each independently Z-Q-, a (hetero)alkyl group or a (hetero)aryl group with the proviso that at least one of R.sup.1, R.sup.2 and R.sup.3 is Z.sub.m-Q-,
Q is a linking group have a valence of m+1;
Z is an ethylenically unsaturated polymerizable group,
m is 1 to 6;
each X.sup.1 is independently O or NR.sup.4, where R.sup.4 is H or C.sub.1-C.sub.4 alkyl, and
n is 0 or 1.

The present invention discloses a phenylate derivative, a preparation method therefor, and a pharmaceutical composition and uses thereof. Specifically, the invention relates to phenylate derivatives represented by formula (I), a pharmaceutically-acceptable salt thereof, a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition containing the one or more compounds, and uses of the compounds in treating diseases related to PD-1/PD-L1 signal channels, such as cancers, infectious diseases and autoimmune diseases.

##STR00001##

A method for producing a carbodiimide compound, comprising a carbodiimide production step of reacting an aliphatic tertiary isocyanate compound (A) in the presence of an organic alkali metal compound (B) having Lewis basicity.

A method for producing a carbodiimide compound, comprising a carbodiimide production step of reacting an aliphatic tertiary isocyanate compound (A) in the presence of an organic alkali metal compound (B) having Lewis basicity.

Provided are compounds of formula (I), or a stereoisomer, mixture of stereoisomers, deuterated analog, tautomer, solvate or pharmaceutically acceptable salt thereof, compositions, method of making and uses thereof.

##STR00001##

Provided are compounds of formula (I), or a stereoisomer, mixture of stereoisomers, deuterated analog, tautomer, solvate or pharmaceutically acceptable salt thereof, compositions, method of making and uses thereof.

##STR00001##